Pathophysiology and recent findings of primary biliary cirrhosis complicated by systemic sclerosis
Corresponding Author
Hiromasa Ohira
Department of Gastroenterology and Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan
Correspondence: Dr Hiromasa Ohira, Department of Gastroenterology and Rheumatology, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1295, Japan. Email: [email protected]Search for more papers by this authorHiroshi Watanabe
Department of Gastroenterology and Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan
Search for more papers by this authorCorresponding Author
Hiromasa Ohira
Department of Gastroenterology and Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan
Correspondence: Dr Hiromasa Ohira, Department of Gastroenterology and Rheumatology, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1295, Japan. Email: [email protected]Search for more papers by this authorHiroshi Watanabe
Department of Gastroenterology and Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan
Search for more papers by this authorAbstract
Primary biliary cirrhosis (PBC) can be complicated by systemic sclerosis (SSc) and, more specifically, limited cutaneous SSc (lcSSc), which was previously called CREST syndrome. Moreover, combined PBC and SSc has been described in many case reports. Although neither the etiology of PBC nor that of SSc has been elucidated, some genetic and immunological factors are known to be shared. Both disorders are autoimmune fibrotic diseases characterized by increased levels of profibrotic cytokines transforming growth factor β (TGFβ) and interleukin-6, which have recently been suggested to influence T-helper 17 cells and regulatory T cells involved in acquired immunity. lcSSc is accompanied by CREST symptoms, although complete CREST cases are rare, with relatively high prevalence of Raynaud's phenomenon, sclerodactyly and telangiectasia, and lower prevalence of calcinosis and esophageal dysmotility. Because patients with anticentromere antibody positive PBC–SSc are at a high risk of developing portal hypertension, particular attention should be paid to the management of gastroesophageal varices. In addition, the management of SSc-related non-hepatic disorders, such as pulmonary fibrosis, pulmonary hypertension, heart disorder, infection and malignancy, is also important for improved outcomes. Because PBC is often complicated by rheumatic disease, hepatologists should keep the possibility of systemic disorder in mind when examining PBC patients.
References
- 1 Kaplan MM, Gerschwin ME. Primary biliary cirrhosis. N Engl J Med 2005; 353: 1261–1273.
- 2 Hirschfield GM, Gershwin ME. The immunobiology and pathophysiology of primary biliary cirrhosis. Annu Rev Pathol 2013; 8: 303–330.
- 3 Folci M, Meda F, Gershwin ME, Selmi C. Cutting-edge issues in primary biliary cirrhosis. Clin Rev Allergy Immunol 2012; 42: 342–354.
- 4 Ishibashi H, Komori A, Shimoda S, Ambrosini YM, Gershwin ME, Nakamura M. Risk factors and prediction of long-term outcome in primary biliary cirrhosis. Intern Med 2011; 50: 1–10.
- 5 Leuschner U. Primary biliary cirrhosis – presentation and diagnosis. Clin Liver Dis 2003; 7: 741–758.
- 6 Kumagi T, Heathcote EJ. Primary biliary cirrhosis. Orphanet J Rare Dis 2008; 3: 1–17.
- 7 LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202–205.
- 8 Hachulla E, Launay D. Diagnosis and classification of systemic sclerosis. Clin Rev Allergy Immunol 2011; 40: 78–83.
- 9 Viswanath V, Phiske MM, Gopalani VV. Systemic sclerosis: current concepts in pathogenesis and therapeutic aspects of dermatological manifestations. Indian J Dermatol 2013; 58: 255–268.
- 10 Winterbauer RH. Multiple teleangiectasi, Raynaud's phenomenon, sclerodactyly, and subcutaneus calcinosis: a syndrome mimicking hereditary hemorrhagic telangiectasia. Bull Johns Hopkins Hosp 1964; 114: 361–383.
- 11 Rodnan GP, Medsger TA Jr, Buekingham RB. Progressive systemic sclerosis-CREST syndrome observation on natural history and late complication in 90 patients. Arthritis Rheum 1975; 18: 423 (abstract).
- 12 Steen VD, Ziegler GL, Rodnan GP, Medsger TA Jr. Clinical and laboratory associations of anticentromere antibody in patients with progressive systemic sclerosis. Arthritis Rheum 1984; 27: 125–131.
- 13 Rigamonti C, Bogdanos DP, Mytilinaiou MG, Smyk DS, Rigopoulou EI, Burroughs AK. Primary biliary cirrhosis associated with systemic sclerosis: diagnostic and clinical challenges. Int. J Rheumatol 2011; 2011: 1–12.
- 14 Murray-Lyon IM, Thompson RP, Ansell ID, Williams R. Scleroderma and primary biliary cirrhosis. Br Med J 1970; 3: 258–259.
- 15 Reynolds TB, Denison EK, Frankl HD, Lieberman FL, Peters RL. Primary biliary cirrhosis with scleroderma, Raynaud's phenomenon and telangiectasia. New syndrome. Am J Med 1971; 50: 302–312.
- 16 Powell FC, Schroeter AL, Dickson ER. Primary biliary cirrhosis and the CREST syndrome: a report of 22 cases. Q J Med 1987; 62: 75–82.
- 17 Fregeau DR, Leung PS, Coppel RL, McNeilage LJ, Medsger TA Jr, Gershwin ME. Autoantibodies to mitochondria in systemic sclerosis. Frequency and characterization using recombinant cloned autoantigen. Arthritis Rheum 1988; 31: 386–392.
- 18 Ito M, Kojima T, Miyata M et al. Primary biliary cirrhosis (PBC)-CREST (calcinosis, Raynaud's phenomenon, esophageal dysfunction, sclerodactyly and telangiectasia) overlap syndrome complicated by Sjögren's syndrome and arthritis. Intern Med 1995; 34: 451–454.
- 19 Nakamura T, Higashi S, Tomoda K, Tsukano M, Sugi K. Primary biliary cirrhosis (PBC)-CREST overlap syndrome with coexistence of Sjögren's syndrome and thyroid dysfunction. Clin Rheumatol 2007; 26: 596–600.
- 20 Assassi S, Fritzler MJ, Arnett FC et al. Primary biliary cirrhosis (PBC), PBC autoantibodies, and hepatic parameter abnormalities in a large population of systemic sclerosis patients. J Rheumatol 2009; 36: 2250–2256.
- 21 Cavazzana I, Ceribelli A, Taraborelli M et al. Primary biliary cirrhosis-related autoantibodies in a large cohort of italian patients with systemic sclerosis. J Rheumatol 2011; 38: 2180–2185.
- 22 Imura-Kumada S, Hasegawa M, Matsushita T et al. High prevalence of primary biliary cirrhosis and disease-associated autoantibodies in Japanese patients with systemic sclerosis. Mod Rheumatol 2012; 22: 892–898.
- 23 Rigamonti C, Shand LM, Feudjo M et al. Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis. Gut 2006; 55: 388–394.
- 24 Gershwin ME, Selmi C, Worman HJ et al. USA PBC Epidemiology Group. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology 2005; 42: 1194–1202.
- 25 Berg PA. The role of the innate immune recognition system in the pathogenesis of primary biliary cirrhosis: a conceptual view. Liver Int 2011; 31: 920–931.
- 26 Hirschfield GM, Invernizzi P. Progress in the genetics of primary biliary cirrhosis. Semin Liver Dis 2011; 31: 147–156.
- 27 Selmi C, De Santis M, Cavaciocchi F, Gershwin ME. Infectious agents and xenobiotics in the etiology of primary biliary cirrhosis. Dis Markers 2010; 29: 287–299.
- 28 Moroncini G, Mori S, Tonnini C, Gabrielli A. Role of viral infections in the etiopathogenesis of systemic sclerosis. Clin Exp Rheumatol 2013; 31: 3–7.
- 29 Dospinescu P, Jones GT, Basu N. Environmental risk factors in systemicsclerosis. Curr Opin Rheumatol 2013; 25: 179–183.
- 30 Broen JC, Coenen MJ, Radstake TR. Genetics of systemic sclerosis: an update. Curr Rheumatol Rep 2012; 14: 11–21.
- 31 Mayo MJ, Jenkins RN, Combes B, Lipsky PE. Association of clonally expanded T cells with the syndrome of primary biliary cirrhosis and limited scleroderma. Hepatology 1999; 29: 1635–1642.
- 32 Tojo J, Ohira H, Suzuki T et al. Clinicolaboratory characteristics of patients with primary biliary cirrhosis associated with CREST symptoms. Hepatol Res 2002; 22: 187–195.
- 33 Dieudé P, Boileau C, Allanore Y. Immunogenetics of systemic sclerosis. Autoimmun Rev 2011; 10: 282–290.
- 34 Barnes BJ, Kellum MJ, Field AE, Pitha PM. Multiple regulatory domains of IRF-5 control activation, cellular localization, and induction of chemokines that mediate recruitment of T lymphocytes. Mol Cell Biol 2002; 22: 5721–5740.
- 35 Takaoka A, Yanai H, Kondo S et al. Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature 2005; 434: 243–249.
- 36 Kyogoku C, Tsuchiya N. A compass that points to lupus: genetic studies on type I interferon pathway. Genes Immun 2007; 8: 445–455.
- 37 Tanaka A, Invernizzi P, Ohira H et al. Replicated association of 17q12-21 with susceptibility of primary biliary cirrhosis in a Japanese cohort. Tissue Antigens 2011; 78: 65–68.
- 38 Ito I, Kawaguchi Y, Kawasaki A et al. Association of a functional polymorphism in the IRF5 region with systemic sclerosis in a Japanese population. Arthritis Rheum 2009; 60: 1845–1850.
- 39 Watford WT, Hissong BD, Bream JH, Kanno Y, Muul L, O'Shea JJ. Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol Rev 2004; 202: 139–156.
- 40 Tsuchiya N, Kawasaki A, Hasegawa M et al. Association of STAT4 polymorphism with systemic sclerosis in a Japanese population. Ann Rheum Dis 2009; 68: 1375–1376.
- 41 Shimoda S, Harada K, Niiro H et al. Interaction between Toll-like receptors and natural killer cells in the destruction of bile ducts in primary biliary cirrhosis. Hepatology 2011; 53: 1270–1281.
- 42 Kikuchi K, Lian ZX, Yang GX et al. Bacterial CpG induces hyper-IgM production in CD27(+) memory B cells in primary biliary cirrhosis. Gastroenterology 2005; 128: 304–312.
- 43 Lafyatis R, York M. Innate immunity and inflammation in systemic sclerosis. Curr Opin Rheumatol 2009; 21: 617–622.
- 44 Ciechomska M, Cant R, Finnigan J, van Laar JM, O'Reilly S. Role of toll-like receptors in systemic sclerosis. Expert Rev Mol Med 2013; 15: e9.
- 45 van Lieshout AW, Vonk MC, Bredie SJ et al. Enhanced interleukin-10 production by dendritic cells upon stimulation with Toll-like receptor 4 agonists in systemic sclerosis that is possibly implicated in CCL18 secretion. Scand J Rheumatol 2009; 38: 282–290.
- 46 van Bon L, Popa C, Huijbens R et al. Distinct evolution of TLR-mediated dendritic cell cytokine secretion in patients with limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2010; 69: 1539–1547.
- 47 van Bon L, Cossu M, Radstake TR. An update on an immune system that goes awry in systemic sclerosis. Curr Opin Rheumatol 2011; 23: 505–510.
- 48 Agarwal SK, Wu M, Livingston CK et al. Toll-like receptor 3 upregulation by type I interferon in healthy and scleroderma dermal fibroblasts. Arthritis Res Ther 2011; 13: R3.
- 49 Moon TC, St Laurent CD, Morris KE et al. Advances in mast cell biology: new understanding of heterogeneity and function. Mucosal Immunol 2010; 3: 111–128.
- 50 Shelburne CP, Abraham SN. The mast cell in innate and adaptive immunity. Adv Exp Med Biol 2011; 716: 162–185.
- 51 Farrell DJ, Hines JE, Walls AF, Kelly PJ, Bennett MK, Burt AD. Intrahepatic mast cells in chronic liver diseases. Hepatology 1995; 22: 1175–1181.
- 52 Akimoto S, Ishikawa O, Igarashi Y, Kurosawa M, Miyachi Y. Dermal mast cells in scleroderma: their skin density, tryptase/chymase phenotypes and degranulation. Br J Dermatol 1998; 138: 399–406.
- 53 Nakamura A, Yamazaki K, Suzuki K, Sato S. Increased portal tract infiltration of mast cells and eosinophils in primary biliary cirrhosis. Am J Gastroenterol 1997; 92: 2245–2249.
- 54 Yukawa S, Yamaoka K, Sawamukai N et al. Dermal mast cell density in fingers reflects severity of skin sclerosis in systemic sclerosis. Mod Rheumatol 2013; 23: 1151–1157.
- 55 Martinez OM, Villanueva JC, Gershwin ME, Krams SM. Cytokine patterns and cytotoxic mediators in primary biliary cirrhosis. Hepatology 1995; 21: 113–119.
- 56 Neuman M, Angulo P, Malkiewicz I et al. Tumor necrosis factor-alpha and transforming growth factor-beta reflect severity of liver damage in primary biliary cirrhosis. J Gastroenterol Hepatol 2002; 17: 196–202.
- 57 Giacomelli R, Cipriani P, Danese C et al. Peripheral blood mononuclear cells of patients with systemic sclerosis produce increased amounts of interleukin 6, but not transforming growth factor beta 1. J Rheumatol 1996; 23: 91–96.
- 58 Scala E, Pallotta S, Frezzolini A et al. Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol 2004; 138: 540–546.
- 59 Fenoglio D, Bernuzzi F, Battaglia F et al. Th17 and regulatory T lymphocytes in primary biliary cirrhosis and systemic sclerosis as models of autoimmune fibrotic diseases. Autoimmun Rev 2012; 12: 300–304.
- 60 Moritoki Y, Lian ZX, Ohsugi Y, Ueno Y, Gershwin ME. B cells and autoimmune liver diseases. Autoimmun Rev 2006; 5: 449–457.
- 61 Pasquali JL, Soulas-Sprauel P, Korganow AS, Martin T. Auto-reactive B cells in transgenic mice. J Autoimmun 2007; 29: 250–256.
- 62 Bosello S, De Luca G, Tolusso B et al. B cells in systemic sclerosis: a possible target for therapy. Autoimmun Rev 2011; 10: 624–630.
- 63 Hasegawa M. B lymphocytes: shedding new light on the pathogenesis of systemic sclerosis. J Dermatol 2010; 37: 3–10.
- 64 Coustet B, Dieudé P, Guedj M et al. C8orf13-BLK is a genetic risk locus for systemic sclerosis and has additive effects with BANK1:results from a large french cohort and meta-analysis. Arthritis Rheum 2011; 63: 2091–2096.
- 65 Nakamura M, Nishida N, Kawashima M et al. Genome-wide association study identifies TNFSF15 and POU2AF1 as susceptibility loci for primary biliary cirrhosis in the Japanese population. Am J Hum Genet 2012; 91: 721–728.
- 66 Hirschfield GM, Xie G, Lu E et al. Association of primary biliary cirrhosis with variants in the CLEC16A, SOCS1, SPIB and SIAE immunomodulatory genes. Genes Immun 2012; 13: 328–335.
- 67 Akimoto S, Ishikawa O, Takagi H, Miyachi Y. Immunological features of patients with primary biliary cirrhosis (PBC) overlapping systemic sclerosis: a comparison with patients with PBC alone. J Gastroenterol Hepatol 1998; 13: 897–901.
- 68 Whyte J, Hough D, Maddison PJ, McHugh NJ. The association of primary biliary cirrhosis and systemic sclerosis is not accounted for by cross reactivity between mitochondrial and centromere antigens. J Autoimmun 1994; 7: 413–424.
- 69 Shoji I, Takagi T, Kasukawa R. Anti-centromere antibody and CREST syndrome in patients with primary biliary cirrhosis. Intern Med 1992; 31: 1348–1355.
- 70 Akimoto S, Ishikawa O, Muro Y, Takagi H, Tamura T, Miyachi Y. Clinical and immunological characterization of patients with systemic sclerosis overlapping primary biliary cirrhosis: a comparison with patients with systemic sclerosis alone. J Dermatol 1999; 26: 18–22.
- 71 Nakamura M, Kondo H, Mori T et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 2007; 45: 118–127.
- 72 Earnshaw W, Bordwell B, Marino C, Rothfield N. Three human chromosomal autoantigens are recognized by sera from patients with anti-centromere antibodies. J Clin Invest 1986; 77: 426–430.
- 73 Robitaille G, Hénault J, Christin MS, Senécal JL, Raymond Y. The nuclear autoantigen CENP-B displays cytokine-like activities toward vascular smooth muscle cells. Arthritis Rheum 2007; 56: 3814–3826.
- 74 Robitaille G, Christin MS, Clément I, Senécal JL, Raymond Y. Nuclear autoantigen CENP-B transactivation of the epidermal growth factor receptor via chemokine receptor 3 in vascular smooth muscle cells. Arthritis Rheum 2009; 60: 2805–2816.
- 75 Ahmed SS, Tan FK, Arnett FC, Jin L, Geng YJ. Induction of apoptosis and fibrillin 1 expression in human dermal endothelial cells by scleroderma sera containing anti-endothelial cell antibodies. Arthritis Rheum 2006; 54: 2250–2262.
- 76 Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005; 35: 35–42.
- 77 Prince M, Chetwynd A, Newman W, Metcalf JV, James OF. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology 2002; 123: 1044–1051.
- 78 Ngu JH, Gearry RB, Frampton CM, Stedman CA. Mortality and the risk of malignancy in autoimmune liver diseases: a population-based study in Canterbury, New Zealand. Hepatology 2012; 55: 522–529.
- 79 Hashimoto A, Tejima S, Tono T et al. Predictors of survival and causes of death in Japanese patients with systemic sclerosis. J Rheumatol 2011; 38: 1931–1939.
- 80 Jacobsen S, Halberg P, Ullman S. Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma). Br J Rheumatol 1998; 37: 750–755.
- 81 Beswick DR, Klatskin G, Boyer JL. Asymptomatic primary biliary cirrhosis. A progress report on long-term follow-up and natural history. Gastroenterology 1985; 89: 267–271.